Register entry
Rosemont Pharmaceuticals Limited
- Registered sites
- 1
- Drug products
- 5
- Live patents
- 16
- Countries
- 1
- Base
- United Kingdom
Authorisation
Registered operations
What the FDA has registered these sites to do. This is the regulatory record, not a marketing claim.
Analytical testingLabellingFinished drug manufacturePackaging
Sites
Facilities
1| Site | Location | Operations | FEI |
|---|---|---|---|
| Rosemont Pharmaceuticals Limited | LeedsUnited Kingdom | Analytical testing, Labelling, Finished drug manufacture, Packaging | 3002442738 |
Exclusivity
Patents
16Unexpired Orange Book patents where this company is the application holder.
| Product | Active ingredient | Expiry |
|---|---|---|
| ATMEKSI | METHOCARBAMOL | Oct 2044 |
| FIBRICOR | FENOFIBRIC ACID | Aug 2027 |
| NEXICLON XR | CLONIDINE | Apr 2027 |
| NEXICLON XR | CLONIDINE | Sept 2031 |
| QDOLO | TRAMADOL HYDROCHLORIDE | Sept 2040 |
| VOSTALLY | RAMIPRIL | Aug 2039 |
Catalogue
Marketed products
5Showing 5 of 5.
| Brand | Generic name | Form | Category |
|---|---|---|---|
| ATMEKSI | methocarbamol | SUSPENSION | NDA |
| Baclofen | Baclofen | SOLUTION | NDA AUTHORIZED GENERIC |
| Nexiclon XR | Clonidine | TABLET, EXTENDED RELEASE | NDA |
| OZOBAX DS | Baclofen | SOLUTION | NDA |
| Ontralfy | Tizanidine Hydrochloride | SOLUTION | NDA |
Provenance
Facility and operations data from the FDA Drug Establishments Current Registration Site. Product data from the openFDA National Drug Code Directory. Patent and exclusivity data from the FDA Orange Book. Shortage data from the FDA drug shortage database. Contact details the FDA publishes for registered establishments are deliberately not reproduced here. This entry is compiled from public records and has not been claimed by the company.